---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-008357"
form_type: "8-K"
ticker: "APGE"
cik: "0001974640"
company_name: "Apogee Therapeutics, Inc."
filed_at: "2025-02-03T23:59:59+00:00"
generated_at: "2026-05-27T04:10:41.126297+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Apogee doses first patient in Part B of Phase 2 APEX trial for APG777 in atopic dermatitis

## Summary
- Part A enrolled 123 patients (exceeded ~110 target) randomized 2:1 APG777 vs placebo; >90% power for primary endpoint.
- Part A 16-week induction data expected mid-2025; maintenance data first half 2026; Part B 16-week data second half 2026.
- APG777 modeled to exceed lebrikizumab exposures by ~30–40% with ~70–90% fewer maintenance injections vs current therapies.
- Plans to initiate Phase 1b combo study of APG777 and APG990 (anti-OX40L) in AD in 2025 with readout in second half 2026.
- Expansion plans include Phase 1b/2b asthma trials in 2025 and Phase 2 EoE trial in 2026.

## SEC filing metadata
- accession: 0001104659-25-008357
- form_type: 8-K
- ticker: APGE
- cik: 0001974640
- company_name: Apogee Therapeutics, Inc.
- filed_at: 2025-02-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1974640/000110465925008357/0001104659-25-008357-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1974640/000110465925008357/tm255268d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-008357
- JSON: https://secwatch.observer/filing/0001104659-25-008357.json
- Plain text: https://secwatch.observer/filing/0001104659-25-008357.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.